Press Releases and Statements Read our latest company news and announcements Image Press Releases Filter and Search Filter by year - Any -20242023202220212020 Search 20 press releases Image December 1, 2023 SINGAPORE Press Release BIOTRONIK Opens New Asia-Pacific Hub in Singapore BIOTRONIK announced today the opening of its new Asia Pacific Manufacturing and Research Hub. The 20,000 m² site will serve as the company’s central hub in Asia-Pacific, with hundreds of employees working in manufacturing, quality, research & development (R&D), and sales and marketing. BIOTRONIK, founded in Berlin, Germany, in 1963 is a pioneer in implantable pacemakers, defibrillators, and vascular intervention for 60 years. BIOTRONIK’s presence in Singapore began in 2012, and in 2016, the company inaugurated its first manufacturing site, complementing its high-quality manufacturing sites in Image November 27, 2023 BÜLACH, Switzerland Press Release Two-Year BIOPACT Randomized Controlled Trial (RCT) Analysis Demonstrates “Persistent Excellence” for Low-Profile Passeo-18 Lux DCB BIOTRONIK announced the presentation of two-year results from the investigator-initiated BIOPACT RCT by Principal Investigator Dr. Koen Deloose at the Paris Vascular Insights 2023 congress. The randomized controlled non-inferiority trial evaluated the safety and efficacy of the Passeo®-18 Lux® drug-coated balloon (DCB) catheter compared to the In.Pact Admiral DCB (Medtronic), and showed excellent results for both balloons through 24 months. 1 The prospective, multicenter, core-lab adjudicated non-inferiority trial enrolled 302 patients in Austria, Belgium, France and Switzerland with Image October 26, 2023 LAKE OSWEGO, Oregon, USA Press Release World’s First Expert Recommendations on Remote Management of Spinal Cord Stimulation Systems Published For the first time, a panel of spinal cord stimulation (SCS) experts has developed best practices in the nascent field of remote SCS device management. The recommendations were recently published in Neuromodulation . 1 When cardiac remote monitoring emerged in the early 2000s, an expert consensus responded by establishing a framework of principles to optimize the management of cardiovascular implantable electronic devices (CIEDs) in 2008. Similar wireless technology is available for the treatment of chronic pain patients, and the publication provides critical guidance on best practices to Image October 5, 2023 LAKE OSWEGO, Oregon, USA Press Release Newly Published Data Supports Effectiveness of BIOTRONIK Neuro’s RESONANCE™ Stimulation Results from the BENEFIT-02 trial – the first of its kind to clinically evaluate a multiphase stimulation paradigm – support the effectiveness of RESONANCE multiphase stimulation used in the BIOTRONIK Neuro Prospera™ Spinal Cord Stimulation (SCS) System in the treatment of patients with chronic pain. In contrast to other currently available SCS therapies, RESONANCE requires less power and uses a proprietary integrated circuit design to deliver a continuous, spatially and temporally distributed therapeutic pulse pattern across the spinal cord. Results of the study were recently published in Image September 1, 2023 AMSTERDAM, The Netherlands Press Release BIOMAG-I Study OCT Analysis Confirmed That BIOTRONIK’s Newest Resorbable Magnesium Scaffold Resorbed at 12 Months New data from the BIOMAG-I first-in-human trial shed light on the vascular healing process following the implantation of DREAMS 3G, BIOTRONIK’s third-generation resorbable magnesium scaffold (RMS). A detailed intravascular optical coherence tomography (OCT) analysis demonstrated that 99.3% of the struts completely degraded at one year. 1 Dr. Masaru Seguchi from the German Heart Centre in Munich, Germany presented the findings at the European Society of Cardiology’s (ESC) congress in Amsterdam. While earlier BIOMAG-I study results provided favorable outcomes with regards to late lumen loss at Image April 19, 2023 BERLIN, Germany Press Release FDA Approval for BIOTRONIK’s Prospera™ Spinal Cord Stimulation System The company today announced U.S. Food and Drug Administration (FDA) approval for Prospera™, a spinal cord stimulation (SCS) system. The system features RESONANCE™, the first and only multiphase stimulation paradigm, paired with Embrace One™, a patient-centric care model that makes proactive care possible by offering automatic, objective, daily remote monitoring and ongoing management and support. 1 This approval marks the launch of the company’s new business segment, BIOTRONIK Neuro . Millions of people all over the world suffer from chronic intractable pain, a severe, constant, and Image April 14, 2023 BERLIN, Germany Press Release DX Technology Demonstrates High Detection Accuracy for Atrial Fibrillation (AF) in Single-Chamber ICD Patients Results from the MATRIX study show that the high detection accuracy of DX single-lead ICD systems for AF episodes (99.7% for ≥ 1h episodes) in combination with the strong transmission performance of BIOTRONIK Home Monitoring ® allows for reliable guideline-recommended remote monitoring of subclinical AF. The findings were published in Europace earlier this week. 1 MATRIX evaluated the utility of the DX-ICD system (atrial signal detection via a floating dipole integrated in the ICD lead) for remotely monitoring atrial high-rate episodes (AHRE) and their duration progression. In addition, the Image April 14, 2023 BERLIN, Germany Press Release DX Technology Demonstrates High Detection Accuracy for Atrial Fibrillation in Single-Chamber ICD Patients Pagination Page 1 Current page 2 Previous page ‹ Previous Subscribe to Our News You must have JavaScript enabled to use this form. Your Name Your Email Subject Message *Fields are mandatory. Latest Blog Posts Show all blog articles Image March 7, 2024 Blog Improving Cardiovascular Health This International Women’s Day Image February 14, 2024 Blog How Love Benefits Your Heart Health Exploring the Science Behind Love's Cardiovascular Benefits Image January 31, 2024 Blog BIOTRONIK Employees Donate Over 14,000 Euros to the Arche Berlin-Hellersdorf A Donation Ceremony Took Place at the Woermannkehre, on January 18, 2024 Press Contact Corporate Public Relations & Communications press@biotronik.com +49 (0) 30 68905 1414 Get in contact
Image December 1, 2023 SINGAPORE Press Release BIOTRONIK Opens New Asia-Pacific Hub in Singapore BIOTRONIK announced today the opening of its new Asia Pacific Manufacturing and Research Hub. The 20,000 m² site will serve as the company’s central hub in Asia-Pacific, with hundreds of employees working in manufacturing, quality, research & development (R&D), and sales and marketing. BIOTRONIK, founded in Berlin, Germany, in 1963 is a pioneer in implantable pacemakers, defibrillators, and vascular intervention for 60 years. BIOTRONIK’s presence in Singapore began in 2012, and in 2016, the company inaugurated its first manufacturing site, complementing its high-quality manufacturing sites in
Image December 1, 2023 SINGAPORE Press Release BIOTRONIK Opens New Asia-Pacific Hub in Singapore BIOTRONIK announced today the opening of its new Asia Pacific Manufacturing and Research Hub. The 20,000 m² site will serve as the company’s central hub in Asia-Pacific, with hundreds of employees working in manufacturing, quality, research & development (R&D), and sales and marketing. BIOTRONIK, founded in Berlin, Germany, in 1963 is a pioneer in implantable pacemakers, defibrillators, and vascular intervention for 60 years. BIOTRONIK’s presence in Singapore began in 2012, and in 2016, the company inaugurated its first manufacturing site, complementing its high-quality manufacturing sites in
Image November 27, 2023 BÜLACH, Switzerland Press Release Two-Year BIOPACT Randomized Controlled Trial (RCT) Analysis Demonstrates “Persistent Excellence” for Low-Profile Passeo-18 Lux DCB BIOTRONIK announced the presentation of two-year results from the investigator-initiated BIOPACT RCT by Principal Investigator Dr. Koen Deloose at the Paris Vascular Insights 2023 congress. The randomized controlled non-inferiority trial evaluated the safety and efficacy of the Passeo®-18 Lux® drug-coated balloon (DCB) catheter compared to the In.Pact Admiral DCB (Medtronic), and showed excellent results for both balloons through 24 months. 1 The prospective, multicenter, core-lab adjudicated non-inferiority trial enrolled 302 patients in Austria, Belgium, France and Switzerland with
Image November 27, 2023 BÜLACH, Switzerland Press Release Two-Year BIOPACT Randomized Controlled Trial (RCT) Analysis Demonstrates “Persistent Excellence” for Low-Profile Passeo-18 Lux DCB BIOTRONIK announced the presentation of two-year results from the investigator-initiated BIOPACT RCT by Principal Investigator Dr. Koen Deloose at the Paris Vascular Insights 2023 congress. The randomized controlled non-inferiority trial evaluated the safety and efficacy of the Passeo®-18 Lux® drug-coated balloon (DCB) catheter compared to the In.Pact Admiral DCB (Medtronic), and showed excellent results for both balloons through 24 months. 1 The prospective, multicenter, core-lab adjudicated non-inferiority trial enrolled 302 patients in Austria, Belgium, France and Switzerland with
Image October 26, 2023 LAKE OSWEGO, Oregon, USA Press Release World’s First Expert Recommendations on Remote Management of Spinal Cord Stimulation Systems Published For the first time, a panel of spinal cord stimulation (SCS) experts has developed best practices in the nascent field of remote SCS device management. The recommendations were recently published in Neuromodulation . 1 When cardiac remote monitoring emerged in the early 2000s, an expert consensus responded by establishing a framework of principles to optimize the management of cardiovascular implantable electronic devices (CIEDs) in 2008. Similar wireless technology is available for the treatment of chronic pain patients, and the publication provides critical guidance on best practices to
Image October 26, 2023 LAKE OSWEGO, Oregon, USA Press Release World’s First Expert Recommendations on Remote Management of Spinal Cord Stimulation Systems Published For the first time, a panel of spinal cord stimulation (SCS) experts has developed best practices in the nascent field of remote SCS device management. The recommendations were recently published in Neuromodulation . 1 When cardiac remote monitoring emerged in the early 2000s, an expert consensus responded by establishing a framework of principles to optimize the management of cardiovascular implantable electronic devices (CIEDs) in 2008. Similar wireless technology is available for the treatment of chronic pain patients, and the publication provides critical guidance on best practices to
Image October 5, 2023 LAKE OSWEGO, Oregon, USA Press Release Newly Published Data Supports Effectiveness of BIOTRONIK Neuro’s RESONANCE™ Stimulation Results from the BENEFIT-02 trial – the first of its kind to clinically evaluate a multiphase stimulation paradigm – support the effectiveness of RESONANCE multiphase stimulation used in the BIOTRONIK Neuro Prospera™ Spinal Cord Stimulation (SCS) System in the treatment of patients with chronic pain. In contrast to other currently available SCS therapies, RESONANCE requires less power and uses a proprietary integrated circuit design to deliver a continuous, spatially and temporally distributed therapeutic pulse pattern across the spinal cord. Results of the study were recently published in
Image October 5, 2023 LAKE OSWEGO, Oregon, USA Press Release Newly Published Data Supports Effectiveness of BIOTRONIK Neuro’s RESONANCE™ Stimulation Results from the BENEFIT-02 trial – the first of its kind to clinically evaluate a multiphase stimulation paradigm – support the effectiveness of RESONANCE multiphase stimulation used in the BIOTRONIK Neuro Prospera™ Spinal Cord Stimulation (SCS) System in the treatment of patients with chronic pain. In contrast to other currently available SCS therapies, RESONANCE requires less power and uses a proprietary integrated circuit design to deliver a continuous, spatially and temporally distributed therapeutic pulse pattern across the spinal cord. Results of the study were recently published in
Image September 1, 2023 AMSTERDAM, The Netherlands Press Release BIOMAG-I Study OCT Analysis Confirmed That BIOTRONIK’s Newest Resorbable Magnesium Scaffold Resorbed at 12 Months New data from the BIOMAG-I first-in-human trial shed light on the vascular healing process following the implantation of DREAMS 3G, BIOTRONIK’s third-generation resorbable magnesium scaffold (RMS). A detailed intravascular optical coherence tomography (OCT) analysis demonstrated that 99.3% of the struts completely degraded at one year. 1 Dr. Masaru Seguchi from the German Heart Centre in Munich, Germany presented the findings at the European Society of Cardiology’s (ESC) congress in Amsterdam. While earlier BIOMAG-I study results provided favorable outcomes with regards to late lumen loss at
Image September 1, 2023 AMSTERDAM, The Netherlands Press Release BIOMAG-I Study OCT Analysis Confirmed That BIOTRONIK’s Newest Resorbable Magnesium Scaffold Resorbed at 12 Months New data from the BIOMAG-I first-in-human trial shed light on the vascular healing process following the implantation of DREAMS 3G, BIOTRONIK’s third-generation resorbable magnesium scaffold (RMS). A detailed intravascular optical coherence tomography (OCT) analysis demonstrated that 99.3% of the struts completely degraded at one year. 1 Dr. Masaru Seguchi from the German Heart Centre in Munich, Germany presented the findings at the European Society of Cardiology’s (ESC) congress in Amsterdam. While earlier BIOMAG-I study results provided favorable outcomes with regards to late lumen loss at
Image April 19, 2023 BERLIN, Germany Press Release FDA Approval for BIOTRONIK’s Prospera™ Spinal Cord Stimulation System The company today announced U.S. Food and Drug Administration (FDA) approval for Prospera™, a spinal cord stimulation (SCS) system. The system features RESONANCE™, the first and only multiphase stimulation paradigm, paired with Embrace One™, a patient-centric care model that makes proactive care possible by offering automatic, objective, daily remote monitoring and ongoing management and support. 1 This approval marks the launch of the company’s new business segment, BIOTRONIK Neuro . Millions of people all over the world suffer from chronic intractable pain, a severe, constant, and
Image April 19, 2023 BERLIN, Germany Press Release FDA Approval for BIOTRONIK’s Prospera™ Spinal Cord Stimulation System The company today announced U.S. Food and Drug Administration (FDA) approval for Prospera™, a spinal cord stimulation (SCS) system. The system features RESONANCE™, the first and only multiphase stimulation paradigm, paired with Embrace One™, a patient-centric care model that makes proactive care possible by offering automatic, objective, daily remote monitoring and ongoing management and support. 1 This approval marks the launch of the company’s new business segment, BIOTRONIK Neuro . Millions of people all over the world suffer from chronic intractable pain, a severe, constant, and
Image April 14, 2023 BERLIN, Germany Press Release DX Technology Demonstrates High Detection Accuracy for Atrial Fibrillation (AF) in Single-Chamber ICD Patients Results from the MATRIX study show that the high detection accuracy of DX single-lead ICD systems for AF episodes (99.7% for ≥ 1h episodes) in combination with the strong transmission performance of BIOTRONIK Home Monitoring ® allows for reliable guideline-recommended remote monitoring of subclinical AF. The findings were published in Europace earlier this week. 1 MATRIX evaluated the utility of the DX-ICD system (atrial signal detection via a floating dipole integrated in the ICD lead) for remotely monitoring atrial high-rate episodes (AHRE) and their duration progression. In addition, the
Image April 14, 2023 BERLIN, Germany Press Release DX Technology Demonstrates High Detection Accuracy for Atrial Fibrillation (AF) in Single-Chamber ICD Patients Results from the MATRIX study show that the high detection accuracy of DX single-lead ICD systems for AF episodes (99.7% for ≥ 1h episodes) in combination with the strong transmission performance of BIOTRONIK Home Monitoring ® allows for reliable guideline-recommended remote monitoring of subclinical AF. The findings were published in Europace earlier this week. 1 MATRIX evaluated the utility of the DX-ICD system (atrial signal detection via a floating dipole integrated in the ICD lead) for remotely monitoring atrial high-rate episodes (AHRE) and their duration progression. In addition, the
Image April 14, 2023 BERLIN, Germany Press Release DX Technology Demonstrates High Detection Accuracy for Atrial Fibrillation in Single-Chamber ICD Patients
Image April 14, 2023 BERLIN, Germany Press Release DX Technology Demonstrates High Detection Accuracy for Atrial Fibrillation in Single-Chamber ICD Patients
Image February 14, 2024 Blog How Love Benefits Your Heart Health Exploring the Science Behind Love's Cardiovascular Benefits
Image February 14, 2024 Blog How Love Benefits Your Heart Health Exploring the Science Behind Love's Cardiovascular Benefits
Image January 31, 2024 Blog BIOTRONIK Employees Donate Over 14,000 Euros to the Arche Berlin-Hellersdorf A Donation Ceremony Took Place at the Woermannkehre, on January 18, 2024
Image January 31, 2024 Blog BIOTRONIK Employees Donate Over 14,000 Euros to the Arche Berlin-Hellersdorf A Donation Ceremony Took Place at the Woermannkehre, on January 18, 2024